Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 108436313 | 10843631 | 3 | F | 20150122 | 20160707 | 20150220 | 20160713 | EXP | US-UCBSA-2015004505 | UCB | 57.61 | YR | F | Y | 122.00000 | KG | 20160713 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 108436313 | 10843631 | 1 | PS | CIMZIA | CERTOLIZUMAB PEGOL | 1 | Subcutaneous | 200 MG, EV 2 WEEKS(QOW); STRENGTH: 200 MG | Y | 125160 | 200 | MG | SOLUTION FOR INJECTION | QOW | |||||
| 108436313 | 10843631 | 2 | C | SULFASALAZINE. | SULFASALAZINE | 1 | UNK, 2X/DAY (BID) | 0 | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 108436313 | 10843631 | 1 | Rheumatoid arthritis |
| 108436313 | 10843631 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 108436313 | 10843631 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 108436313 | 10843631 | Injection site pain | |
| 108436313 | 10843631 | Pneumonia | |
| 108436313 | 10843631 | Treatment failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 108436313 | 10843631 | 1 | 20131015 | 201602 | 0 | |
| 108436313 | 10843631 | 2 | 201310 | 0 |